drugset / Trial / NCT01811706
Dalfampridine and Gait in Spinocerebellar Ataxias
RandomizedCrossoverQuadruple-blindTreatment
Summary
Investigators expect there will be improvement in walking speed and steadiness after taking Dalfampridine, thereby improving activities of daily living and enhancing social and occupational functions for patients with spinocerebellar ataxia.
Timeline
- Start
- 2013-02
- Primary completion
- 2013-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dalfampridine | Small molecule | 10 mg | Oral |